A new long-acting injectable drug called lenacapavir has shown promising results in preventing HIV infection in multiple trials, providing almost complete protection to individuals at risk. However, concerns have been raised regarding the drug’s accessibility due to its high cost and limited availability in middle- and high-income countries where HIV incidence is increasing. The current funding challenges in the Eastern Europe and Central Asia region, as well as the limited access to oral PrEP globally, highlight the need for more affordable prevention strategies to combat the HIV epidemic effectively. The issue of determining access to medicines based on economic status is also brought to light.
Source link
Is Eastern Europe Missing Out?
